And platinum medicine through the Hong Kong Stock Exchange hearing 4 innovative candidate drugs have entered the clinical stage

Screenshot Source: And Platinum Pharmaceuticals And Platinum Pharmaceuticals, founded in 2016, is an innovative biopharmaceutical company dedicated to the development of next-generation immunological and oncology immunotherapy, with Dr. Wang Jinsong, Founder, Chairman and CEO.
Based on the post-hearing data set, the proprietary antibody platform established with Platinum Pharmaceuticals is equipped with a full range of highly efficient antibody discovery and technologies that enhance or amplification antibody efficacy, including the HCAb platform as an extension of important technologies and the HBICETM platform.
since its inception, platinum pharmaceutical through independent innovation research and development and strategic project introduction and other diversified cooperation model, has successfully established a rich and highly innovative strong product pipeline, has 4 products have entered the clinical stage.
FcRn inhibitor Bartoli monoant (HBM9161): a product introduced by And Platinum Pharmaceuticals and enjoying the development and commercialization interests of Greater China.
this product can be used to bind and inhibit specific neonatal Fc subjects (FcRn) to accelerate the removal of IgG antibodies in the body, thereby effectively treating pathogenic IgG-mediated autoimmune diseases.
it has demonstrated its best-in-class potential in existing studies and is being developed as a simpler and more convenient treatment for intraderses.
September, the product completed the first of two Phase 2 clinical trials for severe muscle weakness (MG) and primary immunocomptrophic platelet reduction (ITP).
TNF-α inhibitor Tnasip (HBM9036): and Platinum Pharmaceuticals introduced and enjoyed the development and commercialization interests of Greater China.
is an innovative TNF subject 1 fragment for patients with moderate to severe dry eye disease.
recently, the product for patients with moderate to severe dry eye disease clinical Phase 2 results published, the results show that Tenasip quickly effective, measured by corneal chromosomal score signs significantly improved, and excellent tolerance, comfort and placebo-like.
this provides strong support for Thenassip to conduct Phase 3 clinical registration trials in China.
Tenasip mechanism of action (Screenshot Source: Reference: References) Anti-CTLA-4 Antibody HBM4003: A new generation of all-human anti-CTLA-4 antibodies, is the first in-house developed molecule with platinum medicine.
it has shown unique and good properties in preclinical studies, including the consumption of in-tumor regulatory T-cells by enhancing antibody-dependent cell-mediated cytotoxicity (ADCC).
HBM4003, developed by HCAb, the company's own heavy-chain antibody platform, has great potential for combined treatment with other tumor immune molecules with its low drug exposure characteristics in the serum.
, the product is currently conducting Phase 1 clinical trials for advanced solid tumors in Australia and has been approved by IND in the United States.
september of this year, the clinical trial of HBM4003 monodring therapy and the anti-PD-1 antibody Ripley monoantigen therapy was approved in China.
HER2/CD3 dual-specific antibody HBM9302: and Platinum Pharma were granted exclusive licenses in 2018 to develop a product in Greater China.
It binds to both overexposed HER2 molecules and CD3 molecules expressed on the surface of T cells in solid tumor patients, connecting cytotoxic T cells to HER2-positive cancer cells and playing a cytotoxic effect on tumor cells.
the product showed strong tumor growth inhibition in the anti-curvature bead monoantin model.
, the product is currently being tested by partners in Phase 1 clinical trials in Germany and the United States.
pharmaceutical products in the study (Photo Source: Reference 1) In addition to clinical stage products, and platinum pharmaceutical products have a number of preclinical products worthy of attention.
of these, HBM9022 is an all-human source-to-antibody 47D11 found using a platinum antibody platform, with the potential to prevent and/or treat COVID-19, and the potential to prevent and/or treat other future emerging human diseases caused by the subsovirus saber virus.
HBM9022 demonstrated promising properties in the late preclinical stage, acting in a way that blocks the potential of SARS-CoV-2 and SARS-CoV infection.
the product is currently being developed by And platinum pharmaceuticals in cooperation with AbbVie, the world's leading biopharmaceutical giant.
it is worth noting that platinum medicine also demonstrated its monoclonal antibody HBM1022 developed for CCR8 targets at this year's 16th Protein Engineering Summit (PEGS).
CCR8 is a challenging G-protein coupled subject (GPCR).
data show that HBM1022, developed independently by Platinum Pharmaceuticals, has good anti-tumor function and cross-reacts with crab-eating monkey CCR8.
data show that candidate drugs through targeting CCR8 to achieve effective regulation of tumor micro-environment, whether single or combined, have very good therapeutic potential.
from the platinum medicine official website public information can be founded, the company since its inception, has reached cooperation with a number of companies or research institutions, such as Vir Biotechnology, Hualan gene, Nanjing Tiangang Institute of Immunopharmaceuticals, Zhengda Tianqing and so on.
references: s1 and platinum pharmaceutical prospectus. Retrieved Nov 22, 2020, from s2 and Platinum Pharmaceuticals HKEx IPO prospectos. Retrieved Aug 18, 2020, from s.3 and Platinum Pharmaceutical press releases and public information Source: Pharmaceutical Mission Hills